Yellow fever resurgence: An avoidable crisis?

NPJ Vaccines. 2022 Nov 2;7(1):137. doi: 10.1038/s41541-022-00552-3.

Nicole P Lindsey^{1

2}, Jennifer Horton^{3

4}, Alan D T Barrett^{3

5}, Maurice Demanou^{3

6}, Thomas P Monath^{3

7}, Oyewale Tomori^{3

8}, Michel Van Herp^{3

9}, Herve Zeller^{3

10}, Ibrahima Soce Fall¹¹, Laurence Cibrelus^{3

4}, J Erin Staples^{3

12}

¹ Eliminate Yellow Fever Epidemic Risk Assessment Working Group, Geneva, Switzerland. frd3@cdc.gov.
² Arboviral Diseases Branch, U.S. Centers for Disease Control and Prevention, Fort Collins, CO, USA. frd3@cdc.gov.
³ Eliminate Yellow Fever Epidemic Risk Assessment Working Group, Geneva, Switzerland.
⁴ Eliminate Yellow Fever Epidemics Strategy, High Impact Epidemics, WHO Health Emergencies Programme, World Health Organization, Geneva, Switzerland.
⁵ Department of Pathology and Sealy Institute for Vaccine Sciences, University of Texas Medical Branch, Galveston, TX, USA.
⁶ Regional Office for Africa, World Health Organization, Ouagadougou, Burkina Faso.
⁷ Crozet BioPharma, Lexington, MA, USA.
⁸ African Center for Genomics of Infectious Diseases (ACEGID), Redeemer's University, Ede, Nigeria.
⁹ Médecins Sans Frontières, Brussels, Belgium.
¹⁰ Consultant, Paris, France.
¹¹ WHO Health Emergencies Programme, World Health Organization Headquarters, Geneva, Switzerland.
¹² Arboviral Diseases Branch, U.S. Centers for Disease Control and Prevention, Fort Collins, CO, USA.

No abstract available

Grants and funding